repaglinide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics 2366 135062-02-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • repaglinide
  • (S)-(+)-Repaglinide
  • prandin
  • enyglid
  • surepost
  • Molecular weight: 452.60
  • Formula: C27H36N2O4
  • CLOGP: 5.30
  • LIPINSKI: 1
  • HAC: 6
  • HDO: 2
  • TPSA: 78.87
  • ALOGS: -5.19
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.47 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 56 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.35 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.87 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 22, 1997 FDA NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 571.15 16.96 243 7466 54106 46624247
Lactic acidosis 304.55 16.96 136 7573 33773 46644580
Acute kidney injury 281.58 16.96 263 7446 235592 46442761
Hypoglycaemic coma 137.77 16.96 39 7670 2535 46675818
Hyperkalaemia 109.27 16.96 80 7629 50629 46627724
Drug interaction 87.22 16.96 135 7574 202959 46475394
Sopor 66.00 16.96 41 7668 19787 46658566
Diabetes mellitus inadequate control 61.62 16.96 34 7675 13180 46665173
Pemphigoid 61.31 16.96 26 7683 5665 46672688
Blood glucose increased 59.20 16.96 66 7643 71947 46606406
Metabolic acidosis 51.21 16.96 46 7663 38734 46639619
Transcription medication error 47.68 16.96 10 7699 180 46678173
Confusional state 47.04 16.96 90 7619 159802 46518551
Prothrombin consumption time prolonged 45.84 16.96 8 7701 50 46678303
Hyperglycaemia 45.12 16.96 41 7668 35030 46643323
Anuria 44.12 16.96 26 7683 11405 46666948
Product prescribing error 39.48 16.96 30 7679 20017 46658336
Hepatocellular injury 36.97 16.96 34 7675 29488 46648865
Rhabdomyolysis 35.42 16.96 39 7670 41870 46636483
Medication error 33.75 16.96 33 7676 30878 46647475
Rash maculo-papular 32.78 16.96 31 7678 27843 46650510
Resting tremor 26.25 16.96 8 7701 672 46677681
Rheumatoid arthritis 24.39 16.96 5 7704 240210 46438143
Pancreatitis acute 24.29 16.96 25 7684 24847 46653506
Somnambulism 23.58 16.96 13 7696 5024 46673329
Hypoglycaemic encephalopathy 23.22 16.96 6 7703 275 46678078
Dehydration 22.94 16.96 68 7641 159472 46518881
Drug ineffective 22.71 16.96 49 7660 677789 46000564
Cholestasis 22.67 16.96 25 7684 26868 46651485
Subacute cutaneous lupus erythematosus 21.46 16.96 9 7700 1906 46676447
Dermatitis bullous 20.96 16.96 14 7695 7629 46670724
Vascular purpura 20.89 16.96 8 7701 1338 46677015
Renal failure 20.89 16.96 53 7656 113541 46564812
Autoimmune haemolytic anaemia 19.96 16.96 11 7698 4247 46674106
Pain 19.96 16.96 30 7679 476918 46201435
Death 18.42 16.96 17 7692 335531 46342822
Hypokinesia 18.12 16.96 15 7694 11307 46667046
Drug reaction with eosinophilia and systemic symptoms 17.56 16.96 23 7686 29525 46648828
Asthenia 17.47 16.96 99 7610 310976 46367377
Fall 17.36 16.96 103 7606 328994 46349359

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 560.41 15.45 290 9449 50691 29892048
Lactic acidosis 254.37 15.45 146 9593 31067 29911672
Hypoglycaemic coma 160.34 15.45 50 9689 2281 29940458
Acute kidney injury 139.99 15.45 287 9452 273555 29669184
Drug interaction 87.57 15.45 197 9542 199371 29743368
Oesophageal perforation 63.16 15.45 17 9722 456 29942283
Pemphigoid 55.34 15.45 33 9706 7495 29935244
Cardiac failure 45.28 15.45 90 9649 83328 29859411
Diabetes mellitus inadequate control 43.83 15.45 35 9704 12727 29930012
Erythromelalgia 41.30 15.45 8 9731 44 29942695
Cholestasis 38.57 15.45 44 9695 24906 29917833
Coronavirus infection 38.50 15.45 20 9719 3478 29939261
Polymerase chain reaction 37.47 15.45 8 9731 76 29942663
Hyperkalaemia 35.53 15.45 71 9668 65939 29876800
Acute coronary syndrome 31.95 15.45 30 9709 13543 29929196
Sopor 31.20 15.45 27 9712 10964 29931775
Bradyphrenia 30.79 15.45 18 9721 3939 29938800
Anuria 30.63 15.45 26 9713 10290 29932449
Hepatocellular injury 29.76 15.45 39 9700 25432 29917307
Eosinophilia 29.16 15.45 36 9703 22124 29920615
Hyperkinetic heart syndrome 28.71 15.45 7 9732 125 29942614
Pericardial haemorrhage 27.37 15.45 15 9724 2903 29939836
Urine leukocyte esterase positive 26.46 15.45 8 9731 328 29942411
Renal failure 25.60 15.45 96 9643 128870 29813869
Hyperglycaemia 24.10 15.45 42 9697 35158 29907581
Toxic skin eruption 23.37 15.45 23 9716 10992 29931747
Haemoglobinuria 22.50 15.45 8 9731 548 29942191
Hyperthermia 21.27 15.45 21 9718 10078 29932661
Thrombocytopenia 20.85 15.45 94 9645 136950 29805789
Anaemia 20.84 15.45 127 9612 207865 29734874
Lung disorder 20.83 15.45 37 9702 31432 29911307
Supraventricular extrasystoles 20.71 15.45 13 9726 3231 29939508
Renal tubular necrosis 20.42 15.45 25 9714 15226 29927513
Haematoma 19.64 15.45 31 9708 23922 29918817
Arteriovenous fistula site haematoma 19.35 15.45 4 9735 32 29942707
Extrasystoles 18.89 15.45 13 9726 3769 29938970
Glycosuria 18.88 15.45 9 9730 1302 29941437
Blood glucose decreased 18.46 15.45 22 9717 13031 29929708
Medication error 18.39 15.45 28 9711 20944 29921795
Urine ketone body present 18.11 15.45 8 9731 971 29941768
Death 18.06 15.45 58 9681 357225 29585514
Cardio-respiratory arrest 18.04 15.45 50 9689 57256 29885483
Pancreatitis acute 18.03 15.45 31 9708 25664 29917075
Blood lactic acid increased 17.93 15.45 15 9724 5815 29936924
Vascular purpura 17.20 15.45 9 9730 1588 29941151
Prurigo 16.93 15.45 7 9732 723 29942016
Echocardiogram abnormal 16.91 15.45 7 9732 725 29942014
Loss of consciousness 16.49 15.45 60 9679 79315 29863424
Gamma-glutamyltransferase increased 16.29 15.45 32 9707 29318 29913421
Hypoglycaemic unconsciousness 16.18 15.45 7 9732 809 29941930
Agranulocytosis 16.09 15.45 27 9712 21915 29920824
Chronic kidney disease 16.07 15.45 37 9702 37801 29904938
Pancreatic carcinoma 15.95 15.45 16 9723 7821 29934918

Pharmacologic Action:

SourceCodeDescription
ATC A10BD14 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BX02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Other blood glucose lowering drugs, excl. insulins
FDA EPC N0000175428 Glinide
FDA MoA N0000175448 Potassium Channel Antagonists
MeSH PA D007004 Hypoglycemic Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Alcoholism contraindication 7200002
Asthenia contraindication 13791008
Myocardial infarction contraindication 22298006 DOID:5844
Acute vomiting contraindication 23971007
Severe adrenal insufficiency contraindication 24867002
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Dehydration contraindication 34095006
Infectious disease contraindication 40733004
Ketoacidosis contraindication 56051008
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Acute infectious disease contraindication 63171007
Hypopituitarism contraindication 74728003 DOID:9406
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Cobalamin deficiency contraindication 190634004
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Sepsis syndrome contraindication 238150007
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Traumatic injury contraindication 417746004
Radiography with IV Iodinated Contrast Agent contraindication
Severe Hypoxemia contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.43 acidic
pKa2 3.8 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sulfonylurea receptor 1, Kir6.2 Ion channel BLOCKER Ki 9.14 WOMBAT-PK CHEMBL
Solute carrier organic anion transporter family member 1B1 Transporter WOMBAT-PK
Sulfonylurea receptor 2, Kir6.2 Ion channel BLOCKER Ki 8.81 WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 5.04 CHEMBL
ATP-binding cassette sub-family C member 8 Ion channel Kd 7.30 CHEMBL

External reference:

IDSource
4021119 VUID
N0000148573 NUI
D00594 KEGG_DRUG
4021119 VANDF
C0722725 UMLSCUI
CHEBI:8805 CHEBI
BJX PDB_CHEM_ID
CHEMBL1272 ChEMBL_ID
DB00912 DRUGBANK_ID
6841 IUPHAR_LIGAND_ID
C072379 MESH_SUPPLEMENTAL_RECORD_UI
6818 INN_ID
668Z8C33LU UNII
65981 PUBCHEM_CID
219335 RXNORM
11576 MMSL
120643 MMSL
5416 MMSL
d04267 MMSL
007421 NDDF
109074004 SNOMEDCT_US
386964000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 0574-0240 TABLET 0.50 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 0574-0241 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 0574-0242 TABLET 2 mg ORAL ANDA 25 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 51991-853 TABLET 0.50 mg ORAL ANDA 24 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 51991-854 TABLET 1 mg ORAL ANDA 24 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 51991-855 TABLET 2 mg ORAL ANDA 24 sections
Prandin HUMAN PRESCRIPTION DRUG LABEL 1 54868-5381 TABLET 2 mg ORAL NDA 21 sections
Prandin HUMAN PRESCRIPTION DRUG LABEL 1 54868-6439 TABLET 1 mg ORAL NDA 21 sections
Repaglinide Human Prescription Drug Label 1 57237-157 TABLET 0.50 mg ORAL ANDA 25 sections
Repaglinide Human Prescription Drug Label 1 57237-158 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide Human Prescription Drug Label 1 57237-159 TABLET 2 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 57664-745 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 57664-747 TABLET 2 mg ORAL ANDA 25 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 60429-484 TABLET 0.50 mg ORAL ANDA 24 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 60429-485 TABLET 1 mg ORAL ANDA 24 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 60429-486 TABLET 2 mg ORAL ANDA 24 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 60687-560 TABLET 1 mg ORAL ANDA 25 sections
Prandin HUMAN PRESCRIPTION DRUG LABEL 1 60846-882 TABLET 1 mg ORAL ANDA 28 sections
Prandin HUMAN PRESCRIPTION DRUG LABEL 1 60846-884 TABLET 2 mg ORAL ANDA 28 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8363 TABLET 2 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8447 TABLET 0.50 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8448 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8449 TABLET 2 mg ORAL ANDA 25 sections
Repaglinide Human Prescription Drug Label 1 65862-670 TABLET 0.50 mg ORAL ANDA 27 sections
Repaglinide Human Prescription Drug Label 1 65862-670 TABLET 0.50 mg ORAL ANDA 27 sections
Repaglinide Human Prescription Drug Label 1 65862-671 TABLET 1 mg ORAL ANDA 27 sections
Repaglinide Human Prescription Drug Label 1 65862-671 TABLET 1 mg ORAL ANDA 27 sections
Repaglinide Human Prescription Drug Label 1 65862-672 TABLET 2 mg ORAL ANDA 27 sections
Repaglinide Human Prescription Drug Label 1 65862-672 TABLET 2 mg ORAL ANDA 27 sections
Prandin HUMAN PRESCRIPTION DRUG LABEL 1 68151-3565 TABLET 0.50 mg ORAL NDA 25 sections